Clinical Trial Update: Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing palonosetron plus aprepitant versus palonosetron alone to prevent chemotherapy-induced nausea and vomiting in leukemia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Aloxi (palonosetron hydrochloride)
• EMEND (aprepitant)

Snippet

Sponsor: Associazione Salentina Angela Serra | Conditions: Chemotherapy Induced Nausea and Vomiting | Phase 2 | Status: UNKNOWN